Dendreon Pharmaceuticals

Dendreon Pharmaceuticals is a commercial-stage biopharmaceutical company and a pioneer in the field of cellular immunotherapy. The company is best known for developing PROVENGE (sipuleucel-T), which in 2010 became the first FDA-approved autologous cellular immunotherapy for the treatment of prostate cancer. Dendreon focuses on harnessing the power of the patient's own immune system to fight cancer through advanced antigen identification and cell processing technologies. In recent years, Dendreon has expanded its business model to include contract development and manufacturing organization (CDMO) services. Leveraging its extensive infrastructure and decade-long experience in manufacturing complex cell therapies, the company provides end-to-end manufacturing and logistics support for other biotech partners developing CAR-T, autologous, and allogeneic cell therapies. The company operates major facilities in Seal Beach, California, and Seattle, Washington.